QL1706 + bevacizumab + oxaliplatin + capecitabine

This is a **combination therapy** consisting of: - **QL1706:** A novel bifunctional bispecific antibody that targets both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). QL1706 is composed of a recombinant humanized IgG4 monoclonal antibody (anti-PD-1) and a recombinant humanized IgG1 monoclonal antibody (anti-CTLA-4), uniquely engineered to provide dual immune checkpoint blockade[1][5][3][9]. - **Bevacizumab:** A recombinant humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis[6][2][4][8]. - **Oxaliplatin:** A third-generation platinum-based chemotherapy that induces DNA crosslinking and inhibits DNA synthesis and transcription, leading to apoptosis in cancer cells. - **Capecitabine:** An oral prodrug of 5-fluorouracil (5-FU), a pyrimidine antimetabolite, which is converted in the body to 5-FU and inhibits thymidylate synthase, disrupting DNA synthesis and cell division. This combination leverages immunotherapy (QL1706), antiangiogenic therapy (bevacizumab), and cytotoxic chemotherapy (oxaliplatin, capecitabine) and is being evaluated in clinical trials for advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and other malignancies[7][3][9]. The goal is to synergistically enhance antitumor activity through immune modulation, inhibition of tumor vasculature, and direct cytotoxicity.